Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The evolution of the UK's pandemic response has highlighted the critical importance and economic value of a multi-layered and comprehensive approach to COVID-19.
The need for antibodies and other therapeutics has always been under consideration, the mutation of the virus and the risk this poses on antibody and vaccine efficacy has only recently been properly identified and still requires further academic studies.
These unforeseen circumstances mean there is now a critical, urgent need to procure and deploy a new class of mAbs, that can neutralise any COVID-19 variant. These neutralising mAbs provide protection to a cohort of the population who, for medical reasons, cannot mount an appropriate immune response to vaccination or, for whatever reason, do not get vaccinated and are also at higher risk of hospitalisation or death.
This agreement is for the procurement of 100,008 units of Sotrovimab (VIR-7831).
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| GlaxoSmithKline UK Limited | 04310159 | £1 | LOBBYIST Hill & Knowlton Limited (4 quarters) Global Counsel Ltd (1 quarter) |
Government spending data: This supplier has received £291,004,195 in 110 payments (over £25k) from UK Health Security Agency, Department of Health and Social Care (2021-01-21 to 2026-03-12). View full payment history →